e.g. mhealth
Search Results (1 to 4 of 4 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 3 JMIRx Med
- 1 JMIR Formative Research
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Research Protocols
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Go back to the top of the page Skip and go to footer section
manuscript titled “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis” [1], the authors analyzed over 18 million reports from the Food and Drug Administration (FDA) Adverse Event Reporting System, among which over 17,000 cases were identified to have increased possibility of thyroid hyperplasia and neoplasm when taking glucagon-like peptide-1 (GLP-1) receptor agonist (RA) monotherapy
JMIRx Med 2024;5:e59120
Download Citation: END BibTex RIS
“Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis” [2], the authors analyzed over 18 million reports from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), among which over 17,000 cases were identified to have increased possibility of thyroid hyperplasia and neoplasm when taking glucagon-like peptide-1 (GLP-1) receptor agonist (RA) monotherapy
JMIRx Med 2024;5:e58273
Download Citation: END BibTex RIS
In this study, we evaluated thyroid hyperplasia and neoplasm–related AEs that are reported as being associated with GLP-1 RA monotherapy when compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors monotherapy. SGLT-2 inhibitors, a class of drugs that work by blocking renal glucose reabsorption, were selected as the control cohort due to their comparable indication in diabetes treatment guidelines. We analyzed GLP-1 RAs individually and as a class.
JMIRx Med 2024;5:e55976
Download Citation: END BibTex RIS